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The pleiotropic effects of macrophage migration inhibitory factor (MIF) place it in a central position in
the immunopathogenesis of many diseases. Here we discuss the current understanding of MIF’s role
and highlight it as a potential link between inflammatory activation and malignant progression.Introduction
Macrophage migration inhibitory fac-
tor (MIF) is one of the first cytokine me-
diators to have been described. Efforts
to replicate features of cell-mediated
immunity in vitro in the 1950’s led to
the description of a T-cell-derived fac-
tor that inhibits the migration of mono-
cytes and macrophages—hence, the
name of this cytokine. MIF activity cor-
related with delayed-type hypersensi-
tivity in vitro, and it engendered sub-
stantial interest from immunologists
because it represented a soluble fac-
tor that could be manipulated experi-
mentally. The three-dimensional struc-
ture of MIF subsequently revealed
the protein to define a new structural
superfamily. The MIF-binding receptor
was identified recently by expression
cloning as CD74 (Leng et al., 2003),
which is the cell-surface form of the
MHC class II invariant chain. The ab-
sence of motifs for second-messenger
activation within the short intracyto-
plasmic domain of CD74 then led to
studies establishing that signal trans-
duction requires the recruitment and
activation of an additional protein,
CD44 (Shi et al., 2006). With regard
to signal transduction, MIF has the
unusual ability to stimulate sustained
ERK1 and ERK2 MAP kinase activa-
tion, which is a feature of transforma-
tion by oncogenic Ras mutations. MIF
also has been shown to antagonize
the growth arrest and pro-apoptotic
actions of the tumor suppressor p53
(Hudson et al., 1999), which is induced
in normal cells to limit excessive pro-
inflammatory responses. MIF’s unique
spectrum of activity thus may explainnot only its central role in innate immu-
nity but also long-standing observa-
tions regarding the important role of
persistent or recurrent inflammation
in cancer development.
MIF and Innate Immunity
Murine MIF was cloned after observa-
tions that an immunoregulatory pep-
tide was secreted from corticotrophic
pituitary cells (Bernhagen et al., 1993).
These cells also secrete adrenocorti-
cotrophic hormone, which stimulates
the adrenal secretion of glucocorti-
coids. The neuroendocrine release of
MIF suggested functional interactions
between these pro-inflammatory and
anti-inflammatory mediators, and in
studies of activatedmacrophages,MIF
was shown to specifically counteract
the glucocorticoid-induced suppres-
sion of the cytokine cascade (e.g.,
TNF-a, IL-1b, IL-8) (Calandra et al.,
1995, Donnelly et al., 1997).
The central role of MIF in the innate
immune response first became appar-
ent from studies of models of endo-
toxic shock. These studies revealed
that mortality could be attenuated by
immunoneutralization of MIF (Bernha-
gen et al., 1993). MIF exists preformed
within the cytoplasmic pools of the
macrophage. In contrast, the release
of other cytokines, such as TNF-a,
IL-1b, and IL-8, follows the temporal
delay required for transcriptional acti-
vation and mRNA translation. In mice,
the administration of MIF fully abro-
gated the protective effect of gluco-
corticoids in lethal endotoxic shock,
verifying that the regulatory effect of
MIF on glucocorticoid immunosup-Immunitypression occurs in vivo. Further work
investigated the MIF-glucocorticoid
interaction in an experimental model of
adjuvant arthritis in adrenalectomized
rodents (Leech et al., 2000). Adrenal-
ectomy removes the endogenous
sourceof glucocorticoidsandconverts
experimentally induced arthritis from
a model of remitting disease to a dis-
ease that is rapidly fulminant and lethal.
Anti-MIF fully protected mice from le-
thal arthritis, pointing to the powerful
action ofMIF in upregulating inflamma-
tory pathways when it is unopposed
by endogenous glucocorticoids.
The acute respiratory distress syn-
drome (ARDS) is a classical example of
catastrophic, acute inflammatory lung
injury where there is breakdown of
alveolar capillary integrity and leakage
of excessive exudative fluid into the
pulmonary interstitium and alveolar
airspace. Initial studies identified MIF
as a key inflammatory cytokine driving
ARDS pathogenesis (Donnelly et al.,
1997). In particular, MIF was shown
to override glucocorticoid anti-inflam-
matory activity in ex vivo alveolar cells
derived from patients with ARDS. MIF
also has an important role in the path-
ogenesis of asthma, which is a chronic
inflammatory disease of the lung.
Human eosinophils store substantial
quantities of MIF, and increased MIF
is found within the airways of asth-
matics. In an experimental model of
asthma, mice genetically deficient in
MIF have less pulmonary inflammation
and lower airway hyperresponsive-
ness than genetically matched, wild-
type controls (Rossi et al., 1998, Mizue
et al., 2005).26, March 2007 ª2007 Elsevier Inc. 281
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host MIF response exhibits genetic
control that varies with the allelic form
of thegene.Baughet al. definedapoly-
morphic CATT-repeat element at posi-
tion –794of theMIFpromoter,with five,
six, seven, or eight repeat units defin-
ing individual alleles. A detailed pro-
moter-construct study revealed the
five-CATT allele to have the lowest pro-
moter activity, and the six-, seven-, and
eight-CATT alleles showedproportion-
ally increased gene expression (Baugh
et al., 2002). A significant association
between these MIF polymorphisms
and chronic inflammatory diseases,
including rheumatoid arthritis, cystic
fibrosis, and asthma, have been de-
scribed (Baugh et al., 2002, Plant
et al., 2005, Mizue et al., 2005).
MIF counterregulates glucocorticoid
action by several mechanisms. It upre-
gulates cytoplasmic phospholipase
A2, which is an important target for
the anti-inflammatory actions of gluco-
corticoids. Glucocorticoids also pre-
vent the activation of NF-kB, in part, by
increasing the expression of IkB,which
maintains NF-kB in an inactive form in
the cytosol. MIF also may counteract
the glucocorticoid-mediated inhibition
of NF-kB by overriding the glucocorti-
coid-mediated increase in the cyto-
solic concentrations of Ikb (Daun and
Canon, 2000). Finally, MIF antagonizes
glucocorticoid induction of MAP ki-
nase phosphatase, which is important
in downregulating the MAP-kinase-
activation response (Rogeret al., 2005).
Low, physiologic amounts of gluco-
corticoids stimulate MIF release from
murine monocytes and macrophages
(Calandra et al., 1995). This observa-
tion suggests an importantmechanism
for regulating the functional impact
of the MIF-glucocorticoid interaction.
The glucocorticoid-induced secretion
of MIF is tightly regulated and follows
a bell-shaped dose-response curve.
At high, anti-inflammatory concentra-
tions of glucocorticoids (>108 M),
MIF secretion is prevented. The fact
that MIF is not induced and does not
have an overriding activity at high
concentrations of glucocorticoids
suggests the presence of a ‘‘default’’
mechanism to protect the host against
overwhelming or life-threatening in-
flammatory reactions.282 Immunity 26, March 2007 ª2007 EInhibition of the anti-inflammatory
and immunosuppressive properties of
glucocorticoids is an important mech-
anism of action for MIF’s global,
pro-inflammatory effect. MIF’s posi-
tion within the inflammatory cascade
therefore may be to regulate the mag-
nitude and set point of the immune
and inflammatory response. Thus, inhi-
bition of MIF action offers an attractive
anti-inflammatory therapeutic strategy
because it would act uniquely by
removing the MIF counterregulatory
effect on endogenous or prescribed
glucocorticoids and thereby allow un-
opposed anti-inflammatory activity.
MIF and Sepsis
In the context of microbial infection,
MIF has been shown to upregulate
Toll-like receptor 4, which recognizes
endotoxin (lipolysaccharide, LPS),
and hence to maximize LPS-induced
inflammation (Roger et al., 2001). In
addition, the administration of an MIF
monoclonal antibody, given up to 8 hr
after insult, has been shown to attenu-
ate mortality in mouse models of sep-
sis (Calandra et al., 2000). The obser-
vation that a therapeutic intervention
is efficacious once sepsis has set in
is important given that this situation
mimics the frequent delay to diagnosis
and treatment in clinical practice.
Additional work that focused more
closely on the role of MIF in Gram-
negative infection showed that MIF-
deficient mice have markedly lower
inflammatory responses after pulmo-
nary Pseudomonas aeruginosa infec-
tion than wild-type mice. (Bozza
et al., 1999). Patients with cystic fibro-
sis suffer from chronic Pseudomonas
infection and progressive lung injury
due to an ongoing chronic inflamma-
tory response. A genetic epidemiolog-
ical study of patients with cystic fibro-
sis revealed that those patients with
high-expressionMIF alleles have more
severe end-organ injury as well as
greater Pseudomonas colonization
(Plant et al., 2005).
MIF, Chronic Inflammation,
and Cancer
Defining proliferation, invasion, migra-
tion, and metastasis—the molecular
mechanisms that drive malignant pro-
gression—is essential for understand-lsevier Inc.ing the biology of different cancers
and for developing novel therapies. It
is well recognized from epidemiologi-
cal studies that patients with chronic
inflammatorydiseaseshaveasubstan-
tially increased risk of developing
cancer. For example there is an asso-
ciation between Helicobacter gastritis
and gastric cancer, Barrett’s esopha-
gus and esophageal cancer, inflam-
matory bowel disease and colon
carcinoma, chronic pancreatitis and
pancreatic cancer, cirrhosis and he-
patic cancer, schistosomiasis and
bladder cancer, and osteomyelitis and
osteogenic sarcoma. Defining the host
determinants ofmalignant progression
is presently an area of high interest
in cancer biology. Accumulating evi-
dence of MIF’s unique biological
activities, in particular its role in the
regulation of tumor-suppressor genes,
angiogenesis, and cell senescence,
leads one to postulate that MIF repre-
sents an important link between
chronic inflammation and the develop-
ment of cancer.
MIF Receptor Responses
and Tumorigenesis
Inhibition of MIF or the MIF-binding
receptor CD74 attenuates prostate
cancer invasion (Meyer-Siegler et al.,
2006), and genetic knockdown of MIF
in cancer cell lines reduces tumor-cell
invasiveness (Hagemann et al., 2005).
Activation of the MIF-signaling recep-
tor CD44 leads to cell activation and
a heightened inflammatory response.
However, the long-term activation of
CD44 also plays an important role in
malignancy, and enhanced CD44 acti-
vation has been shown to promote
breast-cancer-cell invasion (Bourgui-
gnon et al., 2003). A recent report has
identified 186 genes that are consid-
ered an ‘‘invasiveness gene signature’’
in CD44+CD24 cells; this gene signa-
ture was associated with an adverse
clinical prognosis not only in breast
cancer but also in lung cancer, pros-
tate cancer, and medulloblastoma
(Liu et al., 2007). Additional work sup-
ports the role of CD44 in promoting
the tethering of circulating tumor cells
to bone-marrow-derived endothelial
cells (Draffen et al., 2004). Collectively,
thebalanceof evidence favors thecon-
cept that CD44 overexpression and
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of metastatic cancer to distant sites.
MIF and the Tumor
Suppressor p53
MIF bypasses p53-mediated growth
arrest or apoptosis (Hudson et al.,
1999). Within the inflammatory sys-
tem, these data provide a mechanism
whereby high MIF concentrations sus-
tain monocyte and macrophage func-
tion in the face of activation-induced
apoptosis (Mitchell et al., 2002). In
the tumor microenvironment, bypass
of p53 by high concentrations of MIF,
expressed intrinsically by transformed
cells or provided by surrounding in-
flammatory cells, would enhance cell
proliferation, extend lifespan, create a
deficient response to genotoxic dam-
age, and allow for the accumulation
of oncogenic mutations. In an initial
report, MIF suppressed the p53-
dependent transcriptional activity of
p21, cyclin G1, and Mdm2 (Hudson
et al., 1999).
MIF-deficient cells do not show en-
hanced proliferation after oncogenic
transformation, and there is evidence
that this defect in oncogenensis is me-
diated by an E2F- and p53-dependent
pathway that is downstream of the RB
tumor suppressor (Petrenko et al.,
2003). Concurrent deletion of the p53
gene completely reversed the ob-
served phenotype of MIF-deficient
cells (Fingerle-Rowson et al., 2003).
More recently, in vivo studies of a mu-
rine Em-Myc lymphoma model have
shown that MIF deficiency is associ-
ated with a delayed onset of B cell lym-
phoma development; this delayed on-
set is mediated by disruption of E2F
activity and the concomitant activation
of the ARF-p53 pathway (Talos et al.,
2005). MIF decreases cellular accu-
mulation of p53 by a pathway involving
ERK activation and the induction of
COX-2 (Mitchell et al., 2002). Both MIF
and COX-2 are higly expressed in
colon carcinoma (Wilson et al., 2005),
and there is evidence that prophylaxis
with NSAIDs reduces the development
of colon adenocarcinomas. Inhibition
of MIF-dependent COX-2 activity
may underlie the protective effect of
these agents and supports a funda-
mental link betweenMIF and p53 func-
tion in a variety of cell systems.MIF and Angiogenesis
The initial description of a role for MIF
in tumorigenesis was based on studies
showing that the administration of
MIF monoclonal antibody in an animal
model of B cell lymphoma resulted
in markedly inhibited tumor growth
and neoangiogenesis (Chesney et al.,
1999). High expression of MIF by mel-
anoma cells and a role for MIF in medi-
ating angiogenesis, tumor growth, and
tumor migration in melanoma were
subsequently reported (Shimizu et al.,
1999).
Building on this work, studies of
human monocytes cocultured with
non-small-cell-lung-cancer cell lines
indicated that tumor-derived MIF was
primarily responsible for the enhanced
secretion of monocyte-derived angio-
genic cytokines. The angiogenic cyto-
kines were principally identified as
CXC chemokines (White et al., 2001).
Elevated amounts of MIF mRNA and
protein are found in hepatocellular car-
cinoma cell lines, and MIF induced a
dose-dependant secretion of IL-8 and
VEGF from these cells (Ren et al.,
2003). Data supporting the role of MIF
in cancer development in the adeno-
matous polyposis coli mouse model
of intestinal tumorigenesis also show
the prominent contribution of neoan-
giogenesis, (Wilson et al., 2005). There
are few data regarding the MIF-signal-
ing pathways that underly this angio-
genic response, althoughboth theERK
and the PI3K pathways are involved
(Amin et al., 2003).
MIF, Tumor Growth, and Hypoxia
Tumor cells both utilize and interact
with the microenvironment of the host
in order to maintain growth advantage.
An upregulation of hypoxic responsive
genes by tumor cells and adjacent,
nontransformed cells contributes to
tumor growth and invasion (Holmquist
et al., 2006). Hypoxia-inducible factor
(HIF) is the master transcriptional
factor responsible for creating the
microenvironment favoring anaerobic
tumor growth, resistance to therapy,
and metastatic adaptation (Pouysse-
gur et al., 2006). Hypoxia also is a
potent inducer of MIF secretion in
transformed cells. Gene-array studies
have shown MIF to be upregulated by
hypoxia in squamous-cell carcinomaImmunit(Koong et al., 2000) and in the MCF-7
breast-cancer cell line (Bando et al.,
2003). Curiously, in colon carcinomas,
hypoxic induction of MIFmay also cor-
relate with sensitivity to apoptosis (Yao
et al., 2005). How these disparate ef-
fects, if confirmed and extended in
different cell types, may be regulated
in the temporal progression of tumor-
ignesis remains to be investigated.
In more recent work, this hypoxia-
induced MIF secretion response was
shown to occur via an HIF-1a-depen-
dent process. (Baugh et al., 2006).
Cells lackingMIF are defective not only
in hypoxia-induced but also in prolyl-
hydroxylase-inhibitor-induced HIF-1a
stabilization. COP9 signalosome sub-
unit 5 (CSN5), a COP9-signalosome
component that interacts functionally
with MIF (Kleemann et al., 2000), has
recently been shown to stabilize HIF-
1a. Further work indicates that MIF-
depleted cells display marked defects
in hypoxia-induced CSN5-HIF-1a in-
teractions. This functional interdepen-
dence between HIF-1a and MIF may
represent an important regulatory axis
for tumor growth and progression
(Winner et al., 2007).
In the context of tumor surveillance,
cellular senescence represents the
consequence of a host surveillance
system that recognises transformed
cells as damaged or abnormal, and it
acts to limit further cell division. There
is increasing evidence that senes-
cence plays an initial, important role
as a tumor suppressor and that the
host may utilize senescence as an
anti-tumor defence mechanism. HIF-
1a delays premature senescence,
and thus activation of HIF-1a in tumor
cells would limit premature senes-
cence and confer a biological advan-
tage on these cells. MIF recently has
been shown to play an important role
in the induction of HIF-1a and delayed
senescence in murine embryonic fi-
broblasts (Winner et al., 2007). Figure 1
summarizes known MIF activation
responses that have been linked to
malignant progression.
Conclusions
Recurrent or persistent inflammation
has long been considered to contrib-
ute to cancer development. Inflamma-
tory-mediated events, such as they 26, March 2007 ª2007 Elsevier Inc. 283
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cules and growth factors, and the
activation of signal-transduction path-
ways that promote cell survival and
proliferation have been hypothesized
to be important factors in cancer pro-
gression. Our emerging understanding
of MIF has established this mediator
as a key, upstream regulator of the in-
nate immune response. MIF’s ability to
drive activation responses by sustain-
ing ERK1 and ERK2 MAP-kinase acti-
vation and by suppressing p53-de-
pendent growth arrest and apoptosis
place it in a unique position to promote
the malignant progression of tumors.
The precise mechanisms that underlie
the functional interaction between MIF
and p53 remain to be elucidated. Cell-
cycle arrest and apoptosis are mecha-
nistically distinct, numerous genes
that are controlled by p53 have been
identified, and the influence of p53 on
the expression of different groups of
genes depends on the nature of stim-
uli. The p53 protein also is known to
undergo extensive posttranslational
modification that affects both its DNA
binding and protein interactions. The
precise mechanisms by which MIF
regulates p53 activation is of high in-
terest for increasing our understanding
of the role of the host microenviron-
ment and inflammation in effecting
tumorigenesis.
It also is evident from recent work
that the intrinsic genetic variation in
MIF production influences the clinical
expression of inflammatory diseases,
and studies are underway to investi-
gate the role of MIF alleles in different
human cancers, especially in the
setting of chronic inflammation. Such
genetically based information will
strengthen the epidemiological rela-
tionship between chronic or recurrent
inflammation and cancer development
and further support the pharmacologic
targeting of MIF-directed pathways,
which may serve to limit the malignant
progression of tumors.
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